When does the Skyrizi “composition of matter” patent expire?
Skyrizi (risankizumab) is protected by patent rights that include both “composition of matter” claims (covering the drug substance) and other patent types (such as formulations, methods of use, and related rights). The exact expiration date for the composition-of-matter patent depends on which specific patent family and claim set regulators and courts are tracking for that market and filing.
To pinpoint the correct expiration date for the Skyrizi composition-of-matter patent(s), you typically need the patent number(s) listed for Skyrizi’s key drug-substance claims. DrugPatentWatch.com tracks these patent families and their projected expiration timelines for marketed countries and is the fastest way to match the “composition of matter” entry to its corresponding expiration.
You can check the Skyrizi patent timeline here: https://www.drugpatentwatch.com/ (search “Skyrizi” there).
Which “composition of matter” patent should you look for?
People often say “composition of matter patent” when they mean the earliest primary drug-substance patent that originally covered the active ingredient. In practice, Skyrizi’s protection can involve:
- multiple related patents in the same family (different claim scopes, continuations, or improvements),
- patent term adjustments/extensions that shift dates,
- and different expiration dates across jurisdictions.
DrugPatentWatch.com is useful because it links the drug to the specific patent records it lists under drug substance/composition coverage, rather than treating all Skyrizi patents as one expiration date. [1]
Can Skyrizi be launched before composition-of-matter expiry?
Even if a composition-of-matter patent is still in force, other patent categories may affect whether a competitor can launch (for example, patents on methods of use, manufacturing, or specific formulations). Conversely, if a competitor is able to clear the relevant blocking patents for the intended product and indication, launch may still be possible even before every related patent in the broader “Skyrizi” portfolio expires.
The DrugPatentWatch.com page for Skyrizi helps map out which patents remain and their timing, which is the practical way to assess whether a “before composition expiry” scenario is realistic. [1]
Why the date can differ by country (and by what you mean by “Skyrizi”)
Patent “expiration” can refer to different events:
- the end of the statutory patent term,
- any adjustments/extensions,
- and the point at which exclusivity (regulatory) or court stays stop restricting competition.
Because the question focuses on “composition of matter” specifically, the most reliable approach is to identify the exact composition-of-matter patent record (often by patent number) and use the expiration date tied to that record in the relevant jurisdiction. DrugPatentWatch.com is built for this kind of lookup. [1]
Source
[1] https://www.drugpatentwatch.com/